Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.

J HaJ KimC JeongY LimM K KimH-S KwonK-H SongM I KangKi Hyun Baek

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

Follow-up raloxifene therapy after denosumab discontinuation resulted in a decrease in bone mass to the pre-denosumab levels and a rebound increase of bone turnover markers. Therefore, raloxifene administered sequentially after denosumab discontinuation was not effective in preventing rebound phenomenon.

Keyphrases

bone mineral density
postmenopausal women
body composition
stem cells
mesenchymal stem cells
replacement therapy
soft tissue